Yoji Komiya Tetsuya Saito Fumitaka Mizoguchi Hitoshi Kohsaka
10.2169/internalmedicine.7966-16
Intern Med
2017;56(23):3237-3241.
tnf inhibitor dermatomyositis hemophagocytic syndrome infliximab
CC BY-NC-ND
https://pubmed.ncbi.nlm.nih.gov/29199203/
Dermatomyositis / complications Dermatomyositis / drug therapy Immunosuppressive Agents / therapeutic use Infliximab / therapeutic use Lymphohistiocytosis, Hemophagocytic / complications Lymphohistiocytosis, Hemophagocytic / drug therapy
Dermatomyositis / complications Dermatomyositis / drug therapy Immunosuppressive Agents / therapeutic use Infliximab / therapeutic use Lymphohistiocytosis, Hemophagocytic / complications Lymphohistiocytosis, Hemophagocytic / drug therapy Case Reports Calcineurin Inhibitors / therapeutic use Drug Therapy, Combination Etoposide / therapeutic use Female Glucocorticoids / therapeutic use Heart Failure / complications Humans Immunoglobulins, Intravenous / therapeutic use Immunosuppressive Agents / administration & dosage Infliximab / administration & dosage Iron Overload / complications Middle Aged Myocarditis / complications Prednisolone / therapeutic use Recurrence Calcineurin Inhibitors Glucocorticoids Immunoglobulins, Intravenous Immunosuppressive Agents Etoposide Prednisolone Infliximab
PMC5742400
29199203
Hemophagocytic Syndrome Complicated with Dermatomyositis Controlled Successfully with Infliximab and Conventional Therapies
2017